Eli Lilly's obesity drugs Foundayo and Zepbound added to CVS Caremark formulary
read at Endpoints ↗RegulatoryPositive
Eli Lilly announced that its two flagship obesity treatments, the oral agent Foundayo and the injectable Zepbound, will be listed on CVS Caremark's drug formularies.
The inclusion comes as the GLP-1 market remains highly competitive, and having the drugs on a major pharmacy benefits manager's list is expected to improve their visibility to prescribers and patients.
Analysts view the coverage decision as a positive catalyst for sales, potentially lifting the company's revenue outlook for its obesity portfolio.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Lilly obesity meds Foundayo and Zepbound to gain CVS coverage”
read at Endpoints ↗83 words · retrieved Jun 3
comments(0)
5-min edit window · permanent after that